	US 12,226,433 B2
	Treatment of irritable bowel syndrome with molybdenum
Pankaj J. Pasricha, Ellicott City, MD (US); Lian Sheng Liu, Ellicott City, MD (US); Qian Li, Ellicott City, MD (US); and Alfred Spormann, Stanford, CA (US)
Assigned to The Johns Hopkins University, Baltimore, MD (US)
Appl. No. 17/266,551
Filed by The Johns Hopkins University, Baltimore, MD (US)
PCT Filed Jul. 22, 2019, PCT No. PCT/US2019/042743 § 371(c)(1), (2) Date Feb. 5, 2021, PCT Pub. No. WO2020/033130, PCT Pub. Date Feb. 13, 2020.
Claims priority of provisional application 62/714,807, filed on Aug. 6, 2018.
Prior Publication US 2021/0308174 A1, Oct. 7, 2021
Int. Cl. A61K 33/00 (2006.01); A61K 9/00 (2006.01); A61K 33/24 (2019.01); A61P 1/00 (2006.01); A61P 1/04 (2006.01); A61P 1/06 (2006.01); A61P 3/02 (2006.01); A61P 29/00 (2006.01)

CPC A61K 33/00 (2013.01) [A61K 9/0053 (2013.01); A61K 33/24 (2013.01); A61P 1/00 (2018.01); A61P 1/04 (2018.01); A61P 1/06 (2018.01); A61P 29/00 (2018.01); A61P 3/02 (2018.01)]

16 Claims

1. A method for treating irritable bowel syndrome (IBS) in a subject having IBS comprising the steps of:

inhibiting growth of bacteria in a gut of the subject, wherein the bacteria are sulfate-reducing bacteria by administering for colonic treatment molybdenum, or a salt, a solvate, or a stereoisomer thereof in a dose amount of at least 100 microgram/kg of body weight to the subject; thereby, treating the IBS of the subject.